fda compounding semaglutide enforcement news november 2025 FDA's GLP-1 decision kicks off 'unprecedented' tussle over shortage FDA and Novo Nordisk Warned

For obesity management, NICE has issued relevant guidance and technology appraisals that define NHS eligibility criteria which are distinct from marketing authorisation alone: NICE TA875 covers semaglutide (Wegovy) for managing overweight and obesity, with specific BMI and comorbidity eligibility criteria and requirements for specialist service involvement

History of Multiple Drug Allergies People with documented allergies to multiple medications may be more prone to reacting to new compounds

Face Wrinkles After Weight Loss Many patients notice new or deeper lines after slimming down

But is a decision truly informed if youre not given all the facts

For individuals with RA considering semaglutide, patience is essential